Ipamorelin

Drug Profile

Ipamorelin

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer Helsinn Therapeutics; Novo Nordisk
  • Class Hormones; Oligopeptides; Small molecules
  • Mechanism of Action Growth hormone releasing factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Gastrointestinal motility disorders; Postoperative ileus
  • Discontinued Growth disorders

Most Recent Events

  • 20 May 2011 Helsinn Therapeutics initiates enrolment in a phase IIb trial for Postoperative ileus in USA (NCT01280344)
  • 28 Jan 2009 Sapphire Therapeutics has been acquired and merged into Helsinn
  • 20 Feb 2007 Phase-I/II clinical trials in Postoperative ileus in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top